Drugs / 99Tc-MDP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03948191 | Oct 2017 → Dec 2018 | disease of orbital part of eye adnexa | Dalian University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02993029 | Sep 2017 → Dec 2027 expected | — | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| — | NCT02304757 | Jan 2015 → Dec 2019 | differentiated thyroid carcinoma, osteoporosis | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99Tc-MDP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02304757 ↗ |
| Known as | 99Technetium-Methylenediphosphonate Injection | “99Tc-MDP(99Technetium-Methylenediphosphonate Injection)” NCT03948191 ↗ |
| Route | Intravenous | “were intravenously administered” NCT02304757 ↗ |